Lipid nanoparticles as the drug carrier for targeted therapy of hepatic disorders

Runxuan Chu, Yi Wang*, Jianglong Kong, Ting Pan, Yani Yang*, Jun He*

*Corresponding author for this work

Research output: Contribution to journalJournal articlepeer-review

1 Citation (Scopus)

Abstract

The liver, a complex and vital organ in the human body, is susceptible to various diseases, including metabolic disorders, acute hepatitis, cirrhosis, and hepatocellular carcinoma. In recent decades, these diseases have significantly contributed to global morbidity and mortality. Currently, liver transplantation remains the most effective treatment for hepatic disorders. Nucleic acid therapeutics offer a selective approach to disease treatment through diverse mechanisms, enabling the regulation of relevant genes and providing a novel therapeutic avenue for hepatic disorders. It is expected that nucleic acid drugs will emerge as the third generation of pharmaceuticals, succeeding small molecule drugs and antibody drugs. Lipid nanoparticles (LNPs) represent a crucial technology in the field of drug delivery and constitute a significant advancement in gene therapies. Nucleic acids encapsulated in LNPs are shielded from the degradation of enzymes and effectively delivered to cells, where they are released and regulate specific genes. This paper provides a comprehensive review of the structure, composition, and applications of LNPs in the treatment of hepatic disorders and offers insights into prospects and challenges in the future development of LNPs.

Original languageEnglish
Pages (from-to)4759-4784
Number of pages26
JournalJournal of Materials Chemistry B
Volume12
Issue number20
Early online date24 Apr 2024
DOIs
Publication statusPublished - 28 May 2024

Scopus Subject Areas

  • Chemistry(all)
  • Biomedical Engineering
  • Materials Science(all)

Fingerprint

Dive into the research topics of 'Lipid nanoparticles as the drug carrier for targeted therapy of hepatic disorders'. Together they form a unique fingerprint.

Cite this